View in EDS HTML Full Text PDF Full Text

Characterization and natural history of patients with LMNA-related dilated cardiomyopathy in the phase 3 REALM-DCM trial.

Saved in:
Bibliographic Details
Title: Characterization and natural history of patients with LMNA-related dilated cardiomyopathy in the phase 3 REALM-DCM trial.
Authors: Garcia-Pavia P; Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.; Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Madrid, Spain.; Centro de Investigación en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.; Universidad Francisco de Vitoria (UFV), Madrid, Spain.; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain., Lakdawala NK; Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Sinagra G; Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy., Ripoll-Vera T; Hospital Universitario Son Llatzer, Mallorca, Spain.; Health Research Institute of the Balearic Islands (IdISBa), Mallorca, Spain.; Department of Medicine, University of the Balearic Islands, Mallorca, Spain.; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Institute of Health Carlos III, Madrid, Spain., Afshar K; Intermountain Heart Institute, Salt Lake City, Utah, USA., Priori SG; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.; IRCCS Istituti Clinici Scientifici Maugeri SpA SB of Pavia, Pavia, Italy.; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Ware JS; National Heart & Lung Institute and MRC London Institute of Medical Sciences, Imperial College London, London, UK.; Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK., Owens A; University of Pennsylvania Heart and Vascular Center, Philadelphia, Pennsylvania, USA., Li H; Pfizer Inc., Collegeville, Pennsylvania, USA., Angeli FS; Pfizer Inc., Collegeville, Pennsylvania, USA., Elliott P; University College London, London, UK., MacRae CA; Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Judge DP; Cardiovascular Genetics, Medical University of South Carolina, Charleston, South Carolina, USA.
Source: ESC heart failure [ESC Heart Fail] 2024 Dec; Vol. 11 (6), pp. 4201-4208. Date of Electronic Publication: 2024 Aug 15.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: John Wiley & Sons Ltd on behalf of the European Society of Cardiology Country of Publication: England NLM ID: 101669191 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2055-5822 (Electronic) Linking ISSN: 20555822 NLM ISO Abbreviation: ESC Heart Fail Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2055-5822
DOI:10.1002/ehf2.14955